D.A. Davidson & CO. Acquires Shares of 136,333 AngioDynamics, Inc. $ANGO

D.A. Davidson & CO. acquired a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 136,333 shares of the medical instruments supplier’s stock, valued at approximately $1,751,000.

Other institutional investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its holdings in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in AngioDynamics during the third quarter valued at approximately $25,000. Washington Trust Advisors Inc. acquired a new stake in AngioDynamics during the third quarter valued at approximately $27,000. State of Wyoming acquired a new stake in AngioDynamics during the second quarter valued at approximately $31,000. Finally, Russell Investments Group Ltd. boosted its holdings in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Trading Up 2.0%

NASDAQ:ANGO opened at $11.16 on Friday. The firm has a 50 day moving average of $10.81 and a 200-day moving average of $11.49. AngioDynamics, Inc. has a 1 year low of $8.36 and a 1 year high of $13.99. The stock has a market capitalization of $461.13 million, a P/E ratio of -14.88 and a beta of 0.37.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The firm had revenue of $78.42 million during the quarter, compared to analysts’ expectations of $76.77 million. As a group, analysts forecast that AngioDynamics, Inc. will post -0.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANGO has been the topic of a number of recent research reports. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Canaccord Genuity Group cut their target price on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.